“…APE1 expression is increased in several cancers such as pancreatic (Jiang et al ., 2010), prostate (Kelley et al ., 2001), cervical (Xu et al ., 1997), gliomas (Bobola et al ., 2004), lung (Yoo et al ., 2008), bladder (Shin et al ., 2015), colon (Lou et al ., 2014), and ovarian cancers (Al‐Attar et al ., 2010; Zhang et al ., 2009), and this increase is associated with resistance to radiation and chemotherapy, leading to poorer patient prognosis (Sharbeen et al ., 2015). Based on its involvement in cancer, and its regulation of several transcription factors associated with cancer‐related pathways, APE1 has become a prime target for anticancer therapies (Fishel and Kelley, 2007; Kelley et al ., 2014).…”